CVD Equipment Provides Strategic Update and Reports Third Quarter 2026 Results

CVD EQUIPMENT CORP (CVV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 enabling tomorrow’s technologies™ 355 South Technology Drive, Central Islip, New York 11722 | T 631.981.7081 | F 631.981.7095 | info@cvdequipment.com CVD Equipment Provides Strategic Update and Reports Third Quarter 2026 Results CENTRAL ISLIP, N.Y. (Business Wire) –

Original reporting
Published Nov 5, 2026, 10:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 10:03 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$CVV
Bearish
high confidence
Mentioned
$CVV
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CVVBearishMed
01

Why it matters

The earnings miss and strategic shift are likely to depress the share price in the short term.

02

Market read

Micro‑cap earnings miss with strategic pivot; limited broader market impact.

03

What to watch

Potential upside from the spare‑parts and quartz services business, which remains cash‑generating.

Relevance 7/10Novelty 6/10Timing: after market today

Background

CVD Equipment Corp filed a Form 8‑K announcing Q3 2026 results and a strategic update that it will no longer pursue new system orders.

Company-level read

Ticker impact

$CVVBearishHigh confidence
Context

The 8‑K reports Q3 2026 results showing a 72% revenue drop, net loss of $2.1 M and a strategic shift away from new system orders.

Expected impact

likely pressure as the market prices in reduced revenue, net loss and the decision to cease new system orders.

Evidence & confidence

The disclosed financials are materially worse than prior year and the company is exiting its core growth line, which typically triggers a sell‑off.

Market effects

Signals weakness in the niche CVD equipment segment, potentially pressuring peers in semiconductor manufacturing equipment.

Limited to U.S. micro‑cap investors; no broad regional effect.

Low; the company is a small cap with niche exposure.

Counterpoint

If the asset sale proceeds and cash burn are sufficient, the company could stabilize and the stock may be undervalued.

Key entities

  • CVD Equipment Corp

    NASDAQ‑listed provider of chemical vapor deposition and related equipment.

  • CBRE, Inc.

    Commercial real‑estate firm engaged to market CVD's real‑estate assets.

Related articles

$CVVMed

CVD Equipment Reports Second Quarter 2026 Results

CVD EQUIPMENT CORP (CVV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 enabling tomorrow’s technologies™ 355 South Technology Drive, Central Islip, New York 11722 | T 631.981.7081 | F 631.981.7095 | info@cvdequipment.com CVD Equipment Reports Second Quarter 2026 Results; Advances Strategic Transformation During Second Quarter, $23.5 Mil

$CVVHighAI 9/10

CVD Equipment (CVV) Q4 2025 Earnings Transcript

CVD Equipment reported Q4 2025 revenue of $5 million, down 33% year over year and sequentially. Gross margin fell to 22.2% and the company posted a net loss of $1.3 million ($0.18/share). Orders were $3.5 million and backlog $6.6 million. It agreed to sell its SDC segment for $16.9 million cash to Atlas Copco, expected to close in Q2 2026.

Med

TELUS (TU) Q3 2026 Earnings Call Transcript

TELUS (TU) outlined three key priorities during its Q3 2026 earnings call: strengthening its financial foundation, honing operational discipline, and deploying resources for growth. The company aims to reduce debt, achieve a net debt to adjusted EBITDA leverage ratio of 3x or lower by 2028, and target $900 million in annualized cash savings by 2028. TELUS plans to monetize non-core assets, streamline operations, and invest in its PureFibre network for growth in AI infrastructure.

$PAHCMedAI 8/10

Phibro Animal (PAHC) Q1 2027 Earnings Call Transcript

Phibro Animal Health (PAHC) reported Q1 2027 sales growth of 6% to $386.8M and adjusted EBITDA growth of 4% to $64.3M. Performance Products and Mineral Nutrition segments drove growth, while Animal Health saw a 3% increase. The company maintained its full-year guidance and expects protein demand to grow, despite near-term pressure on producer profitability.